NCI funds University of Cincinnati Cancer Center study of combination colorectal cancer treatment
Grant and Award Announcement
Updates every hour. Last Updated: 26-Dec-2025 10:11 ET (26-Dec-2025 15:11 GMT/UTC)
The University of Cincinnati Cancer Center’s Joan Garrett, PhD, has received a two-year, approximately $162,000 National Cancer Institute grant to study a new combination approach to treat KRAS-mutated colorectal cancers.
A study led by researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has found that mutations in blood-forming cells may explain the increased risk for leukemia and other blood disorders among first responders exposed to the 9/11 World Trade Center (WTC) disaster site and its toxic dust. The study also points to a novel strategy for use against inflammation and blood disorders associated with environmental toxins. The research was published today in Cancer Discovery, a journal of the American Association for Cancer Research.
The American Association of Immunologists (AAI) today announced the launch of Immunology Explained, a public communications initiative designed to connect people everywhere with clear, science-based information about the immune system and its impact on health. Immunology Explained will cover a broad range of immunology topics including vaccines, autoimmunity, cancer immunotherapy, and infectious diseases.
Phospholipids, essential components of cell membranes, are increasingly recognized for their active roles in regulating innate immunity and inflammation. A new review is published to outline how phospholipid metabolism shapes immune cell behavior, influences the outcome of host defense and tissue homeostasis. The authors also discuss how dysregulation of phospholipid metabolism contributes to inflammatory diseases, such as autoimmune diseases, cardiovascular diseases and cancers, and highlight the potential strategies of restoring phospholipid homeostasis for disease treatment.
A research team from the USC Norris Comprehensive Cancer Center, in collaboration with City of Hope, has found a promising way to adapt CAR T cell therapy so that it can fight solid tumors. The researchers engineered CAR T cells to produce a fusion of two proteins: interleukin 12 (IL-12) cytokine, which boosts immune activity, and a programmed death-ligand 1 (PD-L1) blocker, an immune checkpoint inhibitor that prevents cancer cells from turning off the immune attack. In mouse models of prostate and ovarian cancer, the modified CAR T cells launched a localized attack, shrinking the tumor without causing toxicity in other parts of the body. The results were just published in the journal Nature Biomedical Engineering. The approach enhanced the ability of T cells to penetrate tumors and made the surrounding environment less hostile. It was also safe, with minimal toxicity elsewhere in the body, making it an attractive therapy to translate to patients.